- OralPonatinibIclusigUsed only if resistance to all other agents, or if T315I mutation
- Mechanism of Action
- Inhibit the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.
- Chronic myeloid leukaemia with resistance or intolerance to at least two other tyrosine kinase inhibitors, other with T315I mutation
- Adverse Effects